Aspire Biopharma Holdings (ASBP) Return on Capital Employed (2025 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Return on Capital Employed of 1901.44% for Q1 2026, down 667.41% quarter-over-quarter from 335.11% in Q4 2025.
Aspire Biopharma Holdings (ASBP) Return on Capital Employed (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Return on Capital Employed for 2 consecutive years, with 1901.44% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed changed N/A year-over-year to 1901.44%; the TTM figure through Mar 2026 stood at 1901.44% (changed N/A YoY), while the FY2025 annual figure was 281.98%, up 29643.0% from the prior year.
- Return on Capital Employed eased to 1901.44% in Q1 2026 per ASBP's latest filing, from 335.11% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 335.11% in Q4 2025 and bottomed at 1901.44% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | -84.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -84.69% |
| Mar 31, 2026 | -1,901.44% |
| Dec 31, 2025 | 335.11% |
| Sep 30, 2025 | 144.56% |